Suppr超能文献

一组536例接受血管内治疗的急性缺血性卒中连续患者的当代队列研究结果。

Outcomes of a contemporary cohort of 536 consecutive patients with acute ischemic stroke treated with endovascular therapy.

作者信息

Abilleira Sònia, Cardona Pere, Ribó Marc, Millán Mònica, Obach Víctor, Roquer Jaume, Cánovas David, Martí-Fàbregas Joan, Rubio Francisco, Alvarez-Sabín José, Dávalos Antoni, Chamorro Angel, de Miquel Maria Angeles, Tomasello Alejandro, Castaño Carlos, Macho Juan M, Ribera Aida, Gallofré Miquel

机构信息

From the Stroke Program, Agency for Health Quality and Assessment of Catalonia, Spain (S.A., A.R., M.G.); Hospital de Bellvitge, L'Hospitalet de Llobregat, Spain (P.C., F.R., M.A.d.M.); Hospital Vall d'Hebron, Barcelona, Spain (M.R., J.A.-S., A.T.); Hospital Germans Trias i Pujol, Badalona, Spain (M.M., A.D., C.C.); Hospital Clínic i Provincial, Barcelona, Spain (V.O., A.C., J.M.M.); Hospital del Mar, Barcelona, Spain (J.R.); Hospital de Sabadell, Sabadell, Spain (D.C.); and Hospital de la Santa Creu i Sant Pau, Barcelona, Spain (J.M.-F.).

出版信息

Stroke. 2014 Apr;45(4):1046-52. doi: 10.1161/STROKEAHA.113.003489. Epub 2014 Mar 4.

Abstract

BACKGROUND AND PURPOSE

We sought to assess outcomes after endovascular treatment/therapy of acute ischemic stroke, overall and by subgroups, and looked for predictors of outcome.

METHODS

We used data from a mandatory, population-based registry that includes external monitoring of completeness, which assesses reperfusion therapies for consecutive patients with acute ischemic stroke since 2011. We described outcomes overall and by subgroups (age ≤ or >80 years; onset-to-groin puncture ≤ or >6 hours; anterior or posterior strokes; previous IV recombinant tissue-type plasminogen activator or isolated endovascular treatment/therapy; revascularization or no revascularization), and determined independent predictors of good outcome (modified Rankin Scale score ≤2) and mortality at 3 months by multivariate modeling.

RESULTS

We analyzed 536 patients, of whom 285 received previous IV recombinant tissue-type plasminogen activator. Overall, revascularization (modified Thrombolysis In Cerebral Infarction scores, 2b and 3) occurred in 73.9%, 5.6% developed symptomatic intracerebral hemorrhages, 43.3% achieved good functional outcome, and 22.2% were dead at 90 days. Adjusted comparisons by subgroups systematically favored revascularization (lower proportion of symptomatic intracerebral hemorrhages and death rates and higher proportion of good outcome). Multivariate analyses confirmed the independent protective effect of revascularization. Additionally, age >80 years, stroke severity, hypertension (deleterious), atrial fibrillation, and onset-to-groin puncture ≤6 hours (protective) also predicted good outcome, whereas lack of previous disability and anterior circulation strokes (protective) as well as and hypertension (deleterious) independently predicted mortality.

CONCLUSIONS

This study reinforces the role of revascularization and time to treatment to achieve enhanced functional outcomes and identifies other clinical features that independently predict good/fatal outcome after endovascular treatment/therapy.

摘要

背景与目的

我们试图评估急性缺血性卒中血管内治疗后的总体及亚组结局,并寻找结局的预测因素。

方法

我们使用了一个基于人群的强制性登记系统的数据,该系统包括完整性的外部监测,自2011年起对连续的急性缺血性卒中患者的再灌注治疗进行评估。我们描述了总体及亚组(年龄≤或>80岁;发病至股动脉穿刺≤或>6小时;前循环或后循环卒中;既往静脉注射重组组织型纤溶酶原激活剂或单纯血管内治疗;血管再通或未再通)的结局,并通过多变量建模确定3个月时良好结局(改良Rankin量表评分≤2)和死亡率的独立预测因素。

结果

我们分析了536例患者,其中285例既往接受过静脉注射重组组织型纤溶酶原激活剂治疗。总体而言,血管再通(改良脑梗死溶栓评分,2b和3级)发生率为73.9%,5.6%发生有症状性脑出血,43.3%获得良好功能结局,90天时22.2%死亡。亚组的校正比较系统性地支持血管再通(有症状性脑出血比例和死亡率较低,良好结局比例较高)。多变量分析证实了血管再通的独立保护作用。此外,年龄>80岁、卒中严重程度、高血压(有害)、心房颤动以及发病至股动脉穿刺≤6小时(保护作用)也预测了良好结局,而既往无残疾和前循环卒中(保护作用)以及高血压(有害)独立预测了死亡率。

结论

本研究强化了血管再通和治疗时间在实现更好功能结局方面的作用,并确定了血管内治疗后独立预测良好/致命结局的其他临床特征。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验